taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said..
., seventh-highest in the nation, and more than double the national average... eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..